Navigating a paradigm shift: Bruton’s tyrosine kinase inhibitors redefining the landscape of multiple sclerosis therapy

ElsevierVolume 135, 30 June 2024, 112265International ImmunopharmacologyAuthor links open overlay panelSection snippetsDeclaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References (5)

There are more references available in the full text version of this article.

View full text

© 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

留言 (0)

沒有登入
gif